FAQ on New Therapeutic Developments in Relapsed/Refractory Multiple Myeloma

In this episode, Jesús F. San-Miguel, MD, PhD; Paula Rodriguez-Otero, MD, PhD; and  Prof. Dr. med. Katja Weisel answer questions focused on current and emerging therapies for early and late relapsed, refractory multiple myeloma, with topics including:

• Responses across different subgroups treated with idecabtagene vicleucel in the KarMMa trial
• Selecting therapy for a patient with lenalidomide-refractory disease at first relapse
• How CAR T-cell therapy, melflufen, and selinexor will fit into existing and future treatment algorithms
• Key findings from the DREAMM2 trial on belantamab mafodotin
• Monitoring and management strategies for ocular toxicity with belantamab mafodotin

Content based on an online CME program supported by an educational grant from GlaxoSmithKline.

Link to full program, including associated downloadable slidesets: https://www.clinicaloptions.com/oncology/programs/new tx rr mm